Timing of Radiation Pneumonitis in Patients with Stage 3 Non-Small-Cell Lung Cancer Receiving Consolidation Durvalumab after Chemoradiation

Table 2

Time-to-radiation pneumonitis between patients who had durvalumab vs no durvalumab.

	No durvalumab (n = 19)	Durvalumab (n = 12)	value
Time-to-radiation pneumonitis, month median (range)	2.3 (0.6–9.6)	3.4 (1.7–7.2)	0.01
Early radiation pneumonitis	8 (42%)	2 (17%)	0.14
Late radiation pneumonitis	11 (58%)	10 (83%)